Biomerica, Inc. (NASDAQ:BMRA – Get Free Report) saw a large drop in short interest in the month of August. As of August 31st, there was short interest totaling 116,000 shares, a drop of 72.9% from the August 15th total of 427,700 shares. Based on an average trading volume of 795,400 shares, the short-interest ratio is currently 0.1 days. Currently, 5.0% of the shares of the company are short sold. Currently, 5.0% of the shares of the company are short sold. Based on an average trading volume of 795,400 shares, the short-interest ratio is currently 0.1 days.
Institutional Trading of Biomerica
An institutional investor recently bought a new position in Biomerica stock. Bulltick Wealth Management LLC bought a new position in shares of Biomerica, Inc. (NASDAQ:BMRA – Free Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 137,149 shares of the company’s stock, valued at approximately $78,000. Bulltick Wealth Management LLC owned 5.39% of Biomerica as of its most recent filing with the SEC. Institutional investors and hedge funds own 22.28% of the company’s stock.
Biomerica Stock Performance
Shares of BMRA stock opened at $2.98 on Friday. The company has a market capitalization of $8.40 million, a price-to-earnings ratio of -1.28 and a beta of 0.35. The company has a 50-day simple moving average of $3.22 and a 200 day simple moving average of $3.71. Biomerica has a 52 week low of $2.08 and a 52 week high of $10.16.
Biomerica Company Profile
Biomerica, Inc, a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations.
Featured Stories
- Five stocks we like better than Biomerica
- How to Use the MarketBeat Stock Screener
- Ride the Luxury Retail Wave with These 3 High-End Brand Stocks
- Technology Stocks Explained: Here’s What to Know About Tech
- Wall Street Quietly Bets Big on These Chinese Tech Giants
- What is the Euro STOXX 50 Index?
- Meta’s $600B U.S. Investment: Bearish or Bullish for Shares?
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.
